Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954588 | 1.00 | ATM (0.51) | ATML3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL14000465 | 1.00 | ATM (0.51) | ATML3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL11376989 | 0.88 | KCNH2 (0.50) | ATML3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL11834928 | 0.87 | ACKR3 (0.47) | ATML3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL13621092 | 0.87 | ATM (0.52) | ATML3MBTL1CHRM3CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL11408704 | 0.86 | KCNH2 (0.49) | ATML3MBTL1CHRM3CHRM2CHRM4 | |
| SCHEMBL10869251 | 0.83 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11725897 | 0.83 | ATM (0.49) | ATML3MBTL1CHRM3CHRM4CHRM5 | |
| SCHEMBL13721373 | 0.82 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13590331 | 0.82 | CHRM3 (0.52) | ATML3MBTL1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8592453-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8378121-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| WO-2008103426-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM5, CHRM1 | ATM 3813/4885L3MBTL1 3110/4885CHRM3 4/4885 |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | ATM 3813/4885L3MBTL1 3110/4885CHRM3 4/4885 |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | ATM 3813/4885L3MBTL1 3110/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.